|
gptkbp:instance_of
|
gptkb:chemical_compound
|
|
gptkbp:activities
|
inhibitor of androgen synthesis
|
|
gptkbp:appointed_by
|
oral tablet
|
|
gptkbp:class
|
gptkb:physicist
|
|
gptkbp:clinical_trial
|
gptkb:Europe
gptkb:United_States
high
Phase II
|
|
gptkbp:collaborations
|
with academic institutions
|
|
gptkbp:combatants
|
high affinity for androgen receptors
|
|
gptkbp:composed_of
|
gptkb:chemical_compound
|
|
gptkbp:developed_by
|
gptkb:Allergan
|
|
gptkbp:dissolved
|
soluble in DMSO
slightly soluble in water
|
|
gptkbp:excretion
|
urine
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
ALX-0688
|
|
gptkbp:indication
|
gptkb:castration-resistant_prostate_cancer
gptkb:hormone-sensitive_prostate_cancer
|
|
gptkbp:ingredients
|
C22 H24 N2 O3 S
|
|
gptkbp:interacts_with
|
may interact with anticoagulants
|
|
gptkbp:invention
|
gptkb:Allergan
patented
|
|
gptkbp:is_tested_for
|
clinical trials
|
|
gptkbp:is_used_for
|
treatment of prostate cancer
|
|
gptkbp:lifespan
|
approximately 12 hours
|
|
gptkbp:manager
|
oral
|
|
gptkbp:market
|
not yet marketed
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:products
|
filed
|
|
gptkbp:related_to
|
gptkb:abiraterone
|
|
gptkbp:research_areas
|
endocrinology
oncology
|
|
gptkbp:safety_features
|
generally well tolerated
|
|
gptkbp:side_effect
|
fatigue
nausea
hypertension
hot flashes
|
|
gptkbp:targets
|
CY P17 A1
|
|
gptkbp:type_of
|
123456-78-9
|
|
gptkbp:weight
|
396.56 g/mol
|
|
gptkbp:year_created
|
gptkb:2010
|
|
gptkbp:bfsParent
|
gptkb:Ablynx
|
|
gptkbp:bfsLayer
|
4
|